Michael Newman

Company: Indaptus Therapeutics, Inc.

Job title: Founder & Chief Scientific Officer

Seminars:

Creating Super Donor Cells Post-Donation – Using Attenuated and Killed Bacteria to Induce, Polarize, and Activate Human Innate and Adaptive Immune Cells In Vitro 12:00 pm

Reviewing Indaptus’ clinical stage attenuated and killed, multi-immune agonist Decoy bacterial platform in development for advanced solid tumors Demonstrating induction, polarization, and/or activation of M1 macrophages, NK cells, gamma-delta T cells, and T lymphocytes by Decoy bacteria in vitro Suggesting that GMP Decoy bacteria may represent an ideal treatment to enhance activity and reduce variability during manufacturing of…Read more

day: Conference Day One